These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 28475384)

  • 1. Optimizing pharmacologic management of inflammatory bowel disease.
    Chang S; Hanauer S
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):595-607. PubMed ID: 28475384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis.
    Laube R; Paramsothy S; Leong RW
    Expert Opin Drug Saf; 2021 Mar; 20(3):275-292. PubMed ID: 33412078
    [No Abstract]   [Full Text] [Related]  

  • 3. Current therapy of inflammatory bowel disease in children.
    Rufo PA; Bousvaros A
    Paediatr Drugs; 2006; 8(5):279-302. PubMed ID: 17037946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
    Hagan M; Cross RK
    Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy of ulcerative colitis - current status and emerging trends.
    Ahmad H; Kumar VL
    J Basic Clin Physiol Pharmacol; 2018 Nov; 29(6):581-592. PubMed ID: 30089097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line therapies in inflammatory bowel disease.
    Girardin M; Manz M; Manser C; Biedermann L; Wanner R; Frei P; Safroneeva E; Mottet C; Rogler G; Schoepfer AM
    Digestion; 2012; 86 Suppl 1():6-10. PubMed ID: 23051720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Management of Inflammatory Bowel Disease: a Century of Expert Opinions in Cecil Textbook of Medicine.
    Manu P; Rogozea LM; Dumitraşcu DL
    Am J Ther; 2022 Sep-Oct 01; 29(5):e500-e506. PubMed ID: 36048564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
    Almario CV; Keller MS; Chen M; Lasch K; Ursos L; Shklovskaya J; Melmed GY; Spiegel BMR
    Am J Gastroenterol; 2018 Jan; 113(1):58-71. PubMed ID: 29206816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.
    Wong U; Cross RK
    Expert Opin Investig Drugs; 2019 May; 28(5):473-479. PubMed ID: 30884245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.
    O'Toole A; Moss AC
    Curr Gastroenterol Rep; 2015 Aug; 17(8):32. PubMed ID: 26188882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of biological pharmacotherapy for the treatment of ulcerative colitis.
    Fiorino G; Bonovas S; Cicerone C; Allocca M; Furfaro F; Correale C; Danese S
    Expert Opin Drug Saf; 2017 Apr; 16(4):437-443. PubMed ID: 28279079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
    Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
    Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases.
    Reinglas J; Gonczi L; Kurt Z; Bessissow T; Lakatos PL
    World J Gastroenterol; 2018 Aug; 24(32):3567-3582. PubMed ID: 30166855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical therapy for inflammatory bowel disease.
    Stein RB; Hanauer SB
    Gastroenterol Clin North Am; 1999 Jun; 28(2):297-321. PubMed ID: 10372270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic agents for IBD: practical insights.
    Danese S; Vuitton L; Peyrin-Biroulet L
    Nat Rev Gastroenterol Hepatol; 2015 Sep; 12(9):537-45. PubMed ID: 26284562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Table: safety of drugs for IBD in pregnancy.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):e116. PubMed ID: 30036355
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.